Table 4.
Proportion of CHWs reporting monthly commodity availability by study arm*
| Variable | Intervention, N = 240, % (n) | Control, N = 241, % (n) | All subjects, N = 481, % (n) | PR (95% CI) |
|---|---|---|---|---|
|
Submit drugs report and requisition form using phone: | ||||
| Submitted report |
27.9 (67) |
0.8 (2) |
14.3 (69) |
33.6 (8.8, 128.5) |
|
iCCM commodities available on day of visit: | ||||
| Artemether-lumefantrine |
50.4 (121) |
45.2 (109) |
47.8 (230) |
1.12 (0.82, 1.52) |
| mRDTs |
44.2 (106) |
39.8 (96) |
42.0 (202) |
1.11 (0.80, 1.55) |
| Amoxicillin |
52.5 (126) |
48.1 (116) |
50.3 (242) |
1.09 (0.83, 1.43) |
| ORS |
60.4 (145) |
55.2 (133) |
57.8 (278) |
1.10 (0.59, 1.70) |
| Zinc |
26.7 (64) |
26.6 (24) |
26.6 (128) |
1.01 (0.59, 1.70) |
| All above |
12.9 (31) |
13.3 (32) |
13.1 (63) |
0.98 (0.51, 1.86) |
|
Stockouts of iCCM commodities past month before visit: | ||||
| Artemether-lumefantrine |
30.8 (74) |
33.2 (80) |
32.0 (154) |
0.93 (0.69, 1.26) |
| mRDTs |
35.4 (85) |
35.3 (85) |
35.3 (170) |
1.00 (0.77, 1.31) |
| Amoxicillin |
24.2 (58) |
22.4 (54) |
23.3 (112) |
1.08 (0.71, 1.65) |
| ORS |
11.7 (28) |
11.2 (27) |
11.4 (55) |
1.04 (0.64, 1.68) |
| Zinc |
44.6 (107) |
40.2 (97) |
42.4 (204) |
1.11 (0.75, 1.64) |
|
Received supplies of iCCM commodities ordered: | ||||
| Artemether-lumefantrine |
37.5 (90) |
13.3 (32) |
25.4 (122) |
2.82 (1.50, 5.30) |
| mRDTs |
31.7 (76) |
12.0 (29) |
21.8 (105) |
2.62 (1.37, 5.04) |
| Amoxicillin |
35.8 (86) |
10.0 (24) |
22.9 (110) |
3.59 (1.79, 7.20) |
| ORS |
36.3 (87) |
11.6 (28) |
23.9 (115) |
3.11 (1.70, 5.71) |
| Zinc | 15.0 (36) | 5.0 (12) | 10.0 (48) | 3.01 (1.29, 7.00) |
PR – prevalence ratio, CI – confidence interval, ORS – oral rehydration salts, mRDT – malaria rapid diagnostic tests, iCCM – integrated community case management
* N = Total number of expected commodity reports submitted.